Luigi Celio

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Venues

British journal of cancer

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

The oncologist

Future oncology (London, England)

Fondazione IRCCS Istituto Nazionale dei Tumori

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fondazione IRCCS Istituto Nazionale dei Tumori

Italy

MD :: Medical Oncology

Publications

Luigi Celio, Andrea Antonuzzo, Matti S Aapro
Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)". British journal of cancer (2024)
Luigi Celio, Andrea Antonuzzo, Matti S Aapro
Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)". British journal of cancer 130 (6) (2024)
Luigi Celio, Andrea Antonuzzo, Matti S Aapro
Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)". British journal of cancer (2024)
Luigi Celio, Andrea Antonuzzo, Matti S Aapro
Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)". British journal of cancer 130 (6) (2024)
Luigi Celio, Matti Aapro
Characteristics of nausea and its impact on health-related quality of life in cisplatin-treated patients receiving dexamethasone-sparing prophylaxis: an analysis of the LUNG-NEPA study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 32 (3) (2024)
Luigi Celio, Andrea Antonuzzo, Matti S Aapro
Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)". British journal of cancer 130 (6) (2024)
Luigi Celio, Andrea Antonuzzo, Matti S Aapro
Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)". British journal of cancer 130 (6) (2024)
Luigi Celio, Matti Aapro
Characteristics of nausea and its impact on health-related quality of life in cisplatin-treated patients receiving dexamethasone-sparing prophylaxis: an analysis of the LUNG-NEPA study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 32 (3) (2024)
Luigi Celio, Matti Aapro
Characteristics of nausea and its impact on health-related quality of life in cisplatin-treated patients receiving dexamethasone-sparing prophylaxis: an analysis of the LUNG-NEPA study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 32 (3) (2024)
Luigi Celio, Erminio Bonizzoni, Elena Montani, Matti Aapro
Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis. Future oncology (London, England) 18 (30) (2022)
Matti Aapro, Florian Scotte, Yolanda Escobar, Luigi Celio, Richard Berman, Alessandra Franceschetti, Danielle Bell, Karin Jordan
Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. The oncologist 26 (6) (2021)
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collovà, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta Letizia, Andrea Misino, Angela Gernone, Erminio Bonizzoni, Sara Pilotto, Sabino De Placido, Emilio Bria
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. The oncologist 26 (10) (2021)
Luigi Celio, Erminio Bonizzoni, Emma Zattarin, Paolo Codega, Filippo de Braud, Matti Aapro
Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC cancer 19 (1) (2019)
Nicola Di Renzo, Lorella Melillo, Fernando Porretto, Michela Dargenio, Vincenzo Pavone, Domenico Pastore, Patrizio Mazza, Donato Mannina, Anxur Merenda, Nicola Cascavilla, Giuseppina Greco, Rosella Matera, Erminio Bonizzoni, Luigi Celio, Maurizio Musso
Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese". Cancer medicine 9 (1) (2019)

Luigi Celio.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Luigi Celio